- Actuate Therapeutics (ACTU, Financial) to present Phase 2 data of elraglusib at the ASCO 2025 Annual Meeting.
- The study evaluates elraglusib combined with gemcitabine/nab-paclitaxel for metastatic pancreatic cancer.
- Presentation scheduled for May 31, 2025, in Chicago.
Actuate Therapeutics, Inc. (ACTU), a clinical-stage biopharmaceutical company, has disclosed that the topline data from its Phase 2 trial of elraglusib will be unveiled at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. This announcement highlights the significance of the study, which examined elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) compared to GnP alone for the first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC).
The oral presentation of the study, titled "Preliminary results from the randomized phase 2 study (1801 part 3B) of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) versus GnP alone in patients (pts) with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC)," is slated for May 31, 2025. This session will take place from 3:00 PM to 6:00 PM CDT as part of the Gastrointestinal Cancer session at the conference in Chicago, running from May 30 to June 3.
The outcomes of this study represent a crucial advancement in Actuate Therapeutics' efforts to develop novel therapies targeting glycogen synthase kinase-3 beta (GSK-3β) inhibition, offering potential new treatment avenues for challenging cancer types. The results could signify important progress in improving outcomes for patients facing difficult-to-treat cancers like mPDAC.
